Fundacion PETHEMA — Sponsor Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

2 Recruiting

11 Completed trials

1 Countries active

25 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase III: 3 Phase II: 9 Phase I/II: 2

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

11 of 11 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Acute myeloid leukaemia 2

Top IMPs

BORTEZOMIB 4 DARATUMUMAB 2 IBERDOMIDE 2 LENALIDOMIDE 2 QUIZARTINIB DIHYDROCHLORIDE 2 ANITOCABTAGENE AUTOLEUCEL 1 BELANTAMAB MAFODOTIN 1 CILTACABTAGENE AUTOLEUCEL 1 DECITABINE, CEDAZURIDINE 1 DEXAMETHASONE 1 ELRANATAMAB 1 ISATUXIMAB 1

All trials

14 total

A study to evaluate the safety and efficacy of oral decitabine plus ivosidenib in newly diagnosed adult patients with acute myeloid leukemia… Pending

2025-523238-17-00 Phase II 1 country DECITABINE, CEDAZURIDINE; IVOSIDENIB
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s … Recruiting

2025-522979-29-00 Phase III 1 country QUIZARTINIB DIHYDROCHLORIDE
A multicenter, phase 2 randomized, open label study to evaluate the efficacy and security of zanubrutinib in combination with obinutuzumab i… Recruiting

2023-504647-14-00 Phase II 1 country OBINUTUZUMAB; ZANUBRUTINIB
A Phase 2, open-label study to evaluate the efficacy and safety of anitocabtagene autoleucel in participants with newly diagnosed multiple m… Ended

2024-517020-18-00 Phase II 1 country ANITOCABTAGENE AUTOLEUCEL
An open label, multicenter, phase II study of Elranatamab as single agent for the treatment of relapsed or refractory myeloma in patients pr… Ended

2023-504273-21-00 Phase II 1 country ELRANATAMAB
An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab… Ended

2024-514016-26-00 Phase II 1 country BORTEZOMIB; DARATUMUMAB; TALQUETAMAB; TECLISTAMAB
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended

2024-517008-12-00 Phase III 1 country BORTEZOMIB; IBERDOMIDE; ISATUXIMAB; LENALIDOMIDE
Multicenter, phase II, national and open-label study to evaluate Iberdomide-dexamethasone alone or in combination with standard MM treatment… Ended

2024-518870-15-00 Phase II 1 country DARATUMUMAB; IBERDOMIDE
An open label, multicenter, phase I/II study of belantamab mafodotin in combination with Kd for the treatment of relapsed myeloma patients, … Ended

2024-517006-28-00 Phase I/II 1 country
Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 year… Ended

2024-516905-22-00 Phase III 1 country BORTEZOMIB
Study to evaluate the effectiveness of a combination of 3 treatments, followed by transplantation of their own blood cell progenitor cells f… Ended

2024-516908-42-00 Phase II 1 country POMALIDOMIDE
Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma Halted

2023-510560-12-00 Phase II 1 country CILTACABTAGENE AUTOLEUCEL
A multicentre clinical trial to assess the safety and tolerability of the combination of low-dose cytarabine or azacitidine, plus Venetoclax… Ended

2024-519275-26-00 Phase I/II 1 country QUIZARTINIB DIHYDROCHLORIDE; VENETOCLAX
An open label, multicenter, phase II study of belantamab mafodotin in combination with VRd for the treatment of newly diagnosed transplant e… Ended

2024-516130-35-00 Phase II 1 country BELANTAMAB MAFODOTIN; BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN

Showing 1–14 of 14 trials

← All sponsors A–Z